Leading Addiction Researchers Discuss MN-166 in Symposium on New Approaches in Addiction Treatment

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced the presentation of preliminary results from a Phase 1b study of MN-166 (ibudilast) in methamphetamine addiction at the 75th Annual Meeting of the College on Problems of Drug Dependence (CPDD) in San Diego on June 18, 2013. MN-166 was featured in both a poster session and a symposium at the meeting where leading researchers discussed the role of activated glia, and potential intervention with glial attenuators like MN-166, in drug abuse. Pre-clinical and early clinical results were summarized in the symposium session.

2.1 Million Ounces Gold Inferred at an Average Grade of 1.67 g/t Gold

Nighthawk Gold Corp. ("Nighthawk") (TSX VENTURE:NHK) is pleased to report an updated Inferred Mineral Resource estimate, prepared in accordance with National Instrument 43-101, ("NI 43-101"), of 39.815 million tonnes with an average grade of 1.67 grams per tonne gold for 2.101 million ounces gold using a cut-off grade of 0.6 g/t gold (see Table 1) at its 100%-owned Colomac gold property in the Northwest Territories.

HIGHLIGHTS:

Soltoro Ltd. (TSX VENTURE:SOL) has received positive gold and silver assay results from ongoing mapping and sampling at its 100% owned Tecolote Project in Jalisco, Mexico. The 3,052 hectare Tecolote Project is located less than 10 kilometres north of Soltoro's El Rayo primary silver project and 10 kilometres northeast of Grupo Mexico S.A.B. de C.V.'s El Barqueño property currently optioned to Cayden Resources Inc.

The Carmelita vein system has now been traced for over 100 metres at surface where recent sampling returned numerous high-grade gold and silver values including 27.70 g/t gold and 641 g/t silver over 0.7 metres. A recently completed ground magnetic survey over the Carmelita zone suggests the structure hosting the vein has a strike length of 550 metres. Further mapping and sampling are planned at Carmelita to establish the strike extent of the structure. Selected results from recent sampling are as follows:

Kandi Technologies Group, Inc. (the 'Company' or 'Kandi') (KNDI), today announced, on June 8th, 2013, Hangzhou City started the construction of its first pure electric vehicle (the "EV") smart vertical parking and charging facility in Gudang Technology Park of Xihu District to advance its planned five-year goal of establishing a mini-public transportation system which will include up to 100,000 self-serving rental EVs and all necessary service infrastructure throughout Hangzhou. The first facility is anticipated to be completed and in use in early July of 2013. According to the project plan, over 30 pure EV smart vertical parking and charging facilities (including additional EV sharing service network) will be built by the end of this year in Hangzhou City and 5,000 to 10,000 Kandi pure EVs will be deployed in Hangzhou within one year from the initial launch of the smart vertical parking and charging facility. 

ALL AMOUNTS ARE STATED IN CDN $ (UNLESS NOTED)

Cameco (TSX:CCO)(NYSE:CCJ) announced that the CNSC has granted a uranium mining licence authorizing construction and operation of the Cigar Lake project. The licence will be valid from July 1, 2013 to June 30, 2021.

"We are pleased with this decision," said Tim Gitzel, Cameco's president and CEO. "This licence will allow Cameco to advance the Cigar Lake project into production and shows Canada's nuclear regulator has confidence in our team."

As planned, we expect to begin jet boring in ore this summer, with the first packaged pounds expected in the fourth quarter of this year.

Codexis (CDXS), a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, and Chemtex, a leader in chemical engineering and renewable processes, today announced the successful scale-up in the production of CodeXol® detergent alcohols using cellulosic sugars. The scale-up was achieved at a 1,500 liter demonstration facility at Chemtex’s R&D complex in Tortona, Italy and is a key milestone in the ongoing effort initiated by the two companies to develop a fully integrated biomass to detergent alcohols technology. A combination of Chemtex’s commercially proven PROESA® cellulosic sugar technology and Codexis’ CodeXyme® 4X cellulase enzymes was used to produce cellulosic sugars from non-food biomass, while the CodeXol® detergent alcohol fermentation process technology – which includes Codexis’ proprietary microorganism strain – converted these cellulosic sugars to detergent alcohols.

Verastem, Inc., (VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that VS-6063 has received orphan medicinal product designation from the European Commission for use in mesothelioma. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases. 

 “We are pleased that the EMA recognizes the significant unmet medical need in mesothelioma,” said Christoph Westphal, M.D., Ph.D., Verastem Chairman and Chief Executive Officer. “This orphan drug designation provides us with a number of benefits in the development of VS-6063.” 

 Lundin Petroleum AB (TSX:LUP)(OMX:LUPE) is pleased to announce that its wholly owned subsidiary Lundin Norway AS (Lundin Norway) has been awarded one exploration licence in the 22 nd licensing round.

The awarded licence, PL708, is located in the south eastern Barents Sea. Lundin Norway will be operator with a licence interest of 40 percent. Partners are Edison, North Energy and Lukoil with 20 percent licence interest respectively.

Lundin Petroleum is a Swedish independent oil and gas exploration and production company with a well balanced portfolio of world-class assets primarily located in Europe and South East Asia.

Amgen (AMGN) and Cytokinetics Incorporated (CYTK) today announced an expansion of their strategic collaboration to include Japan.  In 2006, Cytokinetics and Amgen entered into a collaboration to discover, develop and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for potential applications in the treatment of heart failure. Omecamtiv mecarbil is the most advanced drug candidate in this collaboration.  Initially, Cytokinetics` license to Amgen for omecamtiv mecarbil excluded Japan.  Under the amendment to the collaboration announced today, the companies have agreed on terms expanding Amgen`s license for omecamtiv mecarbil and related compounds to include Japan.

North American Energy Partners Inc. ("NAEP" or "the Company") (NOA.TO)(NOA) today announced it has reached an agreement to sell its Piling businesses and announced its financial results for the year and three months ended March 31, 2013.

The Company has prepared its consolidated financial statements in accordance with accounting principles generally accepted in the United States (US GAAP). Except where otherwise specifically indicated, all dollar amounts are expressed in Canadian dollars.

Data presented as a late breaking abstract at SLEEP 2013, the 27th Annual Meeting of Associated Professional Sleep Societies

Vanda Pharmaceuticals Inc. (Vanda) (VNDA) presented additional entrainment and patient-level clinical data at SLEEP 2013, the 27th Annual Meeting of Associated Professional Sleep Societies in Baltimore, from its SET (Safety and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal study of the Efficacy and Safety of Tasimelteon to treat Non-24-Hour Disorder) Phase III studies of tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24) in totally blind individuals.  Non-24 is a serious, rare and chronic circadian rhythm disorder that affects a majority of totally blind individuals who lack light perception and cannot entrain (synchronize) their master body clock to the 24-hour day.  Currently there is no approved FDA treatment for Non-24.

GigOptix, Inc. (NYSE MKT: GIG), a supplier of advanced semiconductor and optical communications components, reiterates continuous strengthening of its position as the lead independent device supplier for 40Gbps/100Gbps high-speed optical interconnects for emerging Cloud and Web 2.0 applications in next generation data centers. 

 “With the ever growing demand for our high-speed devices for optical links using pluggables and active optical cables (AOC), and the recent consolidation of some other merchant component manufacturers into vertically integrated system manufacturers, GigOptix is clearly the largest independent supplier of chip-sets to enable high speed optical interconnects in the data centers for short reach (SR) and long reach (LR) high speed connectivity applications.

Petromanas Energy Inc. ("Petromanas", or the "Company") (TSXV:PMI.V ) today provided an update on current and planned exploration initiatives onshore Albania.

Albania Blocks 2-3

The Shpirag-2 well continues to drill ahead in the target carbonate reservoir at a depth of approximately 5,500 metres. Petromanas intends to drill the well to a target depth of approximately 5,800 metres.

The Company today also announced it has received notification that the Albanian government has approved construction permits for road and lease construction at the Molisht-1 drilling location and two other drilling locations located along the Shpirag structure in Blocks 2-3.

Study Completion Anticipated by Year-End 2013

ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced that the Data Monitoring Committee (DMC) has completed a pre-specified interim analysis of the ICT-107 phase II clinical trial in patients with newly diagnosed glioblastoma and recommended that the company continue the trial to completion.

The trial design for the ICT-107 study provides for the interim analysis to be conducted by the independent DMC after 32 events (patient deaths) are reached.

Preferred Provider Organization network has more than 10 million covered lives; one-in-five Americans now covered for the Rosetta Cancer Origin Test™

Rosetta Genomics Ltd. (ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has executed a credentialing agreement with Three Rivers Provider Network, Inc. (TRPN) of Chula Vista, Calif., for the Rosetta Cancer Origin Test.  TRPN is one of the largest supplemental Preferred Provider Organizations (PPO) in the U.S., providing healthcare benefits to more than 10 million members nationwide.

- The H7 VLP vaccine candidate induces an antibody response after a single dose in mice-

Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a preclinical trial for an H7N9 Avian Influenza VLP vaccine candidate ("H7 vaccine"). The data show that three micrograms of the H7 vaccine administered with and without adjuvant induced high antibody titers after one dose.

Gastar Exploration Ltd. (NYSE MKT: GST) ("Gastar") announced today that the closing of the previously announced sale of Gastar's East Texas properties to Cubic Energy has been extended to June 28, 2013 with a termination date of July 12, 2013 in order to allow Cubic Energy additional time to finalize financing for the transaction.  As compensation for the extension of the closing date, the parties have agreed to reduce certain identified due diligence negative adjustments to the purchase price by $350,000.

 Terra Energy Corp. (TSX:TT) ("Terra" or the "Company") is pleased to announce that Crew Energy Inc. ("Crew") has exercised the option to purchase the balance of Terra's Montney assets in northeast British Columbia for a purchase price of $36 million.

On February 28, 2013, the Company granted Crew an option to acquire the balance of its unconventional Montney assets located in northeast British Columbia for a purchase price of $36 million, subject to typical industry adjustments, by way of a combination of cash or common shares of Crew, with a minimum cash component of $10 million. The option contained restrictions on assignment and had to be exercised by Crew on or before June 3, 2013, with a closing to occur on or before July 9, 2013.

Kandi Technologies Group, Inc. (the 'Company' or 'Kandi') (KNDI), today announced that JL7001BEV, the first pure electric sedan jointly developed by Kandi and Geely Automobile Holdings Ltd. (Hong Kong Stock Exchange, Stock Code: 175) (the "Geely"), has been approved by Ministry of Industry and Information Technology of the People's Republic of China ("MIIT").

According to No. 27 public announcement of MIIT, Kandi Brand/JL7001BEV model is among the latest vehicles on the lists of "Approved Vehicles (No. 248)" and "Recommended Models for Energy Saving & New Energy Vehicle Demonstration and Promotion in China (No. 45)".

– Early Data Show that IPI-145 Is Well Tolerated and Has Activity in a Broad Range of B-Cell and T-Cell Lymphomas, with a 68 Percent Response Rate in Indolent Non-Hodgkin Lymphoma – – Rapid Onset of Clinical Activity Observed, with a Median Time to Response of 1.8 Months –

Infinity Pharmaceuticals, Inc. (INFI) today announced updated Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with relapsed/refractory lymphoma, a group of potentially fatal hematologic malignancies, or blood cancers.